An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.
To support animal studies and clinical pharmacokinetic trials, we developed and validated an automated, specific and highly sensitive LC-MS/MS method for the quantification of naltrexone and 6beta-naltrexol in the same run. In human plasma, the assay had a lower limit of quantitation of only 5pg/mL. This was of critical importance to follow naltrexone pharmacokinetics during its terminal elimination phase. The assay had the following key performance characteristics for naltrexone in human plasma: range of reliable quantification: 0.005-100ng/mL (r2>0.99), inter-day accuracy (0.03ng/mL): 103.7% and inter-day precision: 10.1%. There were no ion suppression, matrix interferences or carry-over.
Clavijo
Claudia
C
Clinical Research & Development, Department of Anesthesiology, University of Colorado Health Sciences Center, Aurora, CO, United States.
Bendrick-Peart
Jamie
J
Zhang
Yan Ling
YL
Johnson
Gillian
G
Gasparic
Antje
A
Christians
Uwe
U
D000818:Animals; D002853:Chromatography, Liquid / Q000379:methods*; D004285:Dogs; D006801:Humans; D015394:Molecular Structure; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000097:blood* / Q000737:chemistry; D009292:Narcotic Antagonists / Q000097:blood / Q000737:chemistry; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*
D009292:Narcotic Antagonists; C010410:6 beta-hydroxynaltrexone; D009271:Naltrexone